Kamada Ltd
Kamada Ltd (KMDA) Option Chain
As of September 17, 2026, Kamada Ltd is trading at $8.85, a +2.08% change from the previous close. The nearest expiration is Oct 16, 2026. Implied volatility is 195.6%. IV Rank is 73%.
Read more
Tracking the KMDA option chain helps you see every strike and expiry on Kamada Ltd in one view, so you can quickly identify the contracts that fit your thesis and your risk. Kamada Ltd's option chain lays out bids, asks, volume, open interest, and Greeks across calls and puts, giving you the full map of KMDA options activity at a glance. Use our scanner to monitor the KMDA option chain in real time and filter for the KMDA options trades that actually meet your criteria.
An option chain is the complete listing of all available option contracts on an underlying, organized by expiration date and strike price. For KMDA stock options, the chain shows side-by-side call and put data, making it easy to compare premiums, assess liquidity, and spot pricing dislocations. Reading the KMDA option chain effectively means looking beyond the last price — implied volatility by strike, volume-to-open-interest ratios, and bid-ask spreads all tell you where KMDA stock options are being actively traded and where they are not.
Kamada Ltd. provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers KAMRAB/KEDRAB for prophylaxis of rabies disease; CYTOGAM for prophylaxis of cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplant; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; VARIZIG for post exposure prophylaxis of varicella; and GLASSIA for intravenous AATD. It also provides KamRho (D) IM for prophylaxis of hemolytic disease of newborns; KamRho (D) IV for immune thermobocytopunic purpura; and snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus.
In addition, the company distributes BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN for Allergic rhinitis and Urticaria; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for cytomegalovirus virus; RUCONEST for angioedema attacks; heparin sodium injection for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. Further, it offers IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis ; and ELIGARD for prostate cancer. The company markets its products through strategic partners in the United States, as well as through distributors internationally. Kamada Ltd. has strategic partnerships with Takeda Pharmaceuticals Company Limited; PARI GmbH; and Kedrion Biopharma. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.
Credit spreads, long calls, iron condors, calendar trades — every strategy starts with the same raw material: a clean, complete option chain. Our scanner pulls Kamada Ltd's full chain across every expiry, highlights the most liquid strikes, and lets you screen KMDA options by the metrics that matter, from IV skew to volume surges. Stop scrolling through endless rows of KMDA stock options — let the full option chain come to you, pre-filtered and ready to trade.
Stock Statistics
- IndustryDrug Manufacturers - Specialty & Generic
- SectorHealthcare
- IV percentile69.05% Elevated
- Market cap (M$)511
- 52 weeks high-5.35%
- 52 weeks low36.15%
- Analyst recommendationStrong Buy
1.00 - Target price$13.50
52.54% above the current stock price - Dividend—
- Payout ratio64.45%
- Earnings date2026-11-09
- P/E23.19
- Future P/E14.83
- EPS (ttm)0.38
- EPS growth next 5 years23.09%
As of September 17, 2026
| CALLs | PUTs | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Prob. OTM % | Open Interest | Volume | Extrinsic Value | Intrinsic Value | Bid | Ask | Strike | Moneyness % | Bid | Ask | Intrinsic Value | Extrinsic Value | Volume | Open Interest | Prob. OTM % |
| 7.72 | 0 | 0 | -0.37 | 3.85 | 1.05 | 5.90 | 5.00 | -42.33 | — | 4.90 | 0.00 | 4.90 | 0 | 0 | 92.28 |
| 39.97 | 148 | 135 | 0.03 | 1.35 | 0.65 | 2.10 | 7.50 | -13.49 | — | 4.90 | 0.00 | 4.90 | 0 | 0 | 60.03 |
| 71.77 | 0 | 0 | 1.40 | 0.00 | — | 1.40 | 10.00 | +15.34 | 0.10 | 4.90 | 1.15 | 1.35 | 0 | 3 | 28.23 |
| 88.88 | 1 | 0 | 4.90 | 0.00 | — | 4.90 | 12.50 | +44.18 | 1.60 | 6.50 | 3.65 | 0.40 | 0 | 0 | 11.12 |
| 95.96 | 0 | 0 | 4.90 | 0.00 | — | 4.90 | 15.00 | +73.01 | 4.10 | 9.00 | 6.15 | 0.40 | 0 | 0 | 4.04 |
As of September 17, 2026
Scan the full option chain in one place
Browse the full KMDA option chain across every strike and expiration, filter by IV, volume, and open interest, and evaluate your trade without switching tools.
Start your 14-day free trial→